Petr Jost

Dr. Petr Jost

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2017 in Molecules
Verified
Journal Article
Open access
PDF file
KSKatarina Spilovska
Katarina Spilovska
Jan KorabecnyJan Korabecny
Jan Korabecny
VHVendula Hepnarova
Vendula Hepnarova
DJDaniel Jun
Daniel Jun
MHMartina Hrabinova
Martina Hrabinova
Kamil KucaKamil Kuca
Kamil Kuca
A novel series of 6-chlorotacrine-scutellarin hybrids was designed, synthesized and the biological activity as potential anti-Alzheimer’s agents was assessed. Their inhibitory activity towards human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBChE), antioxidant activity, ability to cross the blood-brain barrier (BBB) and hepatotoxic profile were evaluated in vitro. Among these compounds, hybrid K1383, bearing two methylene tether between two basic scaffolds, was found to be very potent hAChE inhibitor (IC50 = 1.63 nM). Unfortunately, none of the hybrids displayed any antioxidant activity (EC50 ≥ 500 μM). Preliminary data also suggests a comparable hepatotoxic profile with 6-Cl-THA (established on a HepG2 cell line). Kinetic studies performed on hAChE with the most active compound in the study, K1383, pointed out to a mixed, non-competitive enzyme inhibition. These findings were further corroborated by docking studies.

1 July 2015 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
PJPetr Jost
Petr Jost
HSHana Svobodova
Hana Svobodova
RSRudolf Stetina
Rudolf Stetina

28 July 2017 in Molecules
Verified
Journal Article
Open access
PDF file
EMEva Mezeiova
Eva Mezeiova
Jan KorabecnyJan Korabecny
Jan Korabecny
VHVendula Hepnarova
Vendula Hepnarova
MHMartina Hrabinova
Martina Hrabinova
PJPetr Jost
Petr Jost
Kamil KucaKamil Kuca
Kamil Kuca
Tacrine (THA), the first clinically effective acetylcholinesterase (AChE) inhibitor and the first approved drug for the treatment of Alzheimer’s disease (AD), was withdrawn from the market due to its side effects, particularly its hepatotoxicity. Nowadays, THA serves as a valuable scaffold for the design of novel agents potentially applicable for AD treatment. One such compound, namely 7-methoxytacrine (7-MEOTA), exhibits an intriguing profile, having suppressed hepatotoxicity and concomitantly retaining AChE inhibition properties. Another interesting class of AChE inhibitors represents Huprines, designed by merging two fragments of the known AChE inhibitors—THA and (−)-huperzine A. Several members of this compound family are more potent human AChE inhibitors than the parent compounds. The most promising are so-called huprines X and Y. Here, we report the design, synthesis, biological evaluation, and in silico studies of 2-methoxyhuprine that amalgamates structural features of 7-MEOTA and huprine Y in one molecule.

Verified
Journal Article
Open access
PDF file
LCLucie Cechakova
Lucie Cechakova
MOMartin Ondrej
Martin Ondrej
VPVojtěch Pavlík
Vojtěch Pavlík
PJPetr Jost
Petr Jost
DCDana Cizkova
Dana Cizkova
ATAles Tichy
Ales Tichy
Autophagy inhibition through small-molecule inhibitors is one of the approaches to increase the efficiency of radiotherapy in oncological patients. A new inhibitor—Lys05—with the potential to accumulate within lysosomes and to block autophagy was discovered a few years ago. Several studies have addressed its chemosensitizing effects but nothing is known about its impact in the context of ionizing radiation (IR). To describe its role in radiosensitization, we employed radioresistant human non-small cell lung carcinoma cells (H1299, p53-negative). Combined treatment of H1299 cells by Lys05 together with IR decreased cell survival in the clonogenic assay and real-time monitoring of cell growth more than either Lys05 or IR alone. Immunodetection of LC3 and p62/SQSTM1 indicated that autophagy was inhibited, which correlated with increased SQSTM1 and decreased BNIP3 gene expression determined by qRT-PCR. Fluorescence microscopy and flow cytometry uncovered an accumulation of lysosomes. Similarly, transmission electron microscopy demonstrated the accumulation of autophagosomes confirming the ability of Lys05 to potentiate autophagy inhibition in H1299 cells. We report here for the first time that Lys05 could be utilized in combination with IR as a promising future strategy in the eradication of lung cancer cells.

9 February 2018 in Drug and Chemical Toxicology
Verified
Journal Article
Closed access
LMLubica Muckova
Lubica Muckova
JPJaroslav Pejchal
Jaroslav Pejchal
PJPetr Jost
Petr Jost
NVNela Vanova
Nela Vanova
DHDavid Herman
David Herman
DJDaniel Jun
Daniel Jun
The development of acetylcholinesterase reactivators, i.e., antidotes against organophosphorus poisoning, is an important goal of defense research. The aim of this study was to compare cytotoxicity and chemical structure of five currently available oximes (pralidoxime, trimedoxime, obidoxime, methoxime, and asoxime) together with four perspective oximes from K-series (K027, K074, K075, and K203). The cytotoxicity of tested substances was measured using two methods – colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay and impedance based real-time cytotoxicity assay – in three different cell lines (HepG2, ACHN, and NHLF). Toxicity was subsequently expressed as toxicological index IC50. The tested compounds showed different cytotoxicity ranging from 0.92 to 40.06 mM. In HepG2 cells, K027 was the least and asoxime was the most toxic reactivator. In ACHN and NHLF cell lines, trimedoxime was the compound with the lowest adverse effects, whereas the highest toxicity was found in methoxime-treated cells. The results show that at least five structural features affect the reactivators’ toxicity such as the number of oxime groups in the molecule, their position on pyridinium ring, the length of carbon linker, and the oxygen substitution or insertion of the double bond into the connection chain. Newly synthetized oximes with IC50 ≥ 1 mM evaluated in this three cell lines model might appear suitable for further testing.

1 June 2017 in Toxicology Letters
Verified
Journal Article
Closed access
PJPetr Jost
Petr Jost
PFPetra Fikrova
Petra Fikrova
HSHana Svobodova
Hana Svobodova
JPJaroslav Pejchal
Jaroslav Pejchal
RSRudolf Stetina
Rudolf Stetina